These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15124979)

  • 1. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
    Wysocki J; Belowski D; Kalina M; Kochanski L; Okopien B; Kalina Z
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):212-7. PubMed ID: 15124979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.
    Krysiak R; Stachura-Kułach A; Okopień B
    Pharmacol Rep; 2010; 62(1):120-30. PubMed ID: 20360622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
    Després JP; Lemieux I; Salomon H; Delaval D
    J Intern Med; 2002 Jun; 251(6):490-9. PubMed ID: 12028504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
    Yong QW; Thavintharan S; Cheng A; Chew LS
    Ann Acad Med Singap; 1999 Nov; 28(6):778-82. PubMed ID: 10672386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
    Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
    Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.
    Ducobu J; VanHaelst L; Salomon H
    J Cardiovasc Pharmacol; 2003 Jan; 41(1):60-7. PubMed ID: 12500022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
    Sharpe M; Ormrod D; Jarvis B
    Am J Cardiovasc Drugs; 2002; 2(2):125-32; discussion 133-4. PubMed ID: 14727988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
    Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
    Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
    Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.
    Cavallero E; Dachet C; Assadolahi F; Martin C; Navarro N; Ansquer JC; Corda C; Foucher C; Juhan-Vague I; Jacotot B
    Atherosclerosis; 2003 Jan; 166(1):151-61. PubMed ID: 12482562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
    Capell WH; DeSouza CA; Poirier P; Bell ML; Stauffer BL; Weil KM; Hernandez TL; Eckel RH
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):307-13. PubMed ID: 12588776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.